Navigation Links
Press Statement Issued by Ranbaxy Laboratories Limited
Date:2/25/2009

GURGAON, India, Feb. 25 /PRNewswire/ -- Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxy's Paonta Sahib facility have been added to a list maintained under a policy entitled "Application Integrity Policy" or "AIP". Ranbaxy will analyze the letter and other information fully and respond appropriately in a timely manner.

The FDA has said it has no evidence the drugs on the market are substandard and also that they comply with specifications upon testing.

No products from Ranbaxy's other manufacturing facilities are included in the AIP.

Ranbaxy will continue to co-operate with the USFDA. Further, no effort or action will be spared to timely protect key ANDAs from Paonta Sahib, which include some First to File applications.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

    Company Contacts for Media:

    India Contacts:

    Ramesh L. Adige
    President - Corporate Affairs and Global Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135000
    e-mail: ramesh.adige@ranbaxy.com

    or

    Raghu Kochar
    Director - Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135141 / Mob: 9811617256
    e-mail: raghu.kochar@ranbaxy.com

    or

    Krishnan Ramalingam
    Sr. Manager - Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135143 / Mob: 9810042540
    e-mail: krishnan.ramalingam@ranbaxy.com

    USA Contact:

    Charles M. Caprariello
    Vice President, Corporate Communications
    Ranbaxy Inc.
    (609) 720-5615
    email : chuck.caprariello@ranbaxy.com


'/>"/>
SOURCE Ranbaxy Laboratories Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. Clinical depression linked to abnormal emotional brain circuits
4. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
5. Specific antagonism lowers blood pressure
6. Are too many people diagnosed as depressed?
7. Depression Taking Toll on Returning U.S. Vets
8. Doctors Often Miss High Blood Pressure in Kids
9. Pill box organizers increase HIV patients adherence and improve viral suppression
10. Damp, Moldy Homes May Cause Depression
11. Treating depression may improve recovery of heart rate variability following coronary syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... of America (UCAOA) and College of Urgent Care Medicine will host industry leaders ... sessions and speakers will help those in the industry adapt to the issues ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to accept ... a hearing aid doesn’t have the stigma it had when great-grandpa wore his hearing ... Greater Boston, in a NALA North American Speaker Series (NASS) segment. “He ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: